Table 1.
Anti-CHIKV antibodies and its distribution in relation to sex, age and location of study participants.
| Variable | No. of Participant | Proportion %) |
No.%) of specific anti-CHIKV-Abs |
Total anti-CHIKV-Abs | |||||
|---|---|---|---|---|---|---|---|---|---|
| IgM only | IgG only | IgM+IgG | |||||||
| Gender | |||||||||
| Male | 110 | 45.3 | 8 (7.3) | 32 (29.1) | 5 (4.5) | 45 (40.9) | |||
| Female | 133 | 54.7 | 6 (4.5) | 29 (21.8) | 3 (2.3) | 38 (28.6) | |||
| Total | 243 | 100 | 14 (5.8) | 61 (25.1) | 8 (3.3) | 83 (34.2) | |||
| X2 | 4.075 | ||||||||
| P-value | 0.044 | ||||||||
| Age | |||||||||
| 5–14 | 37 | 15.2 | 1 (2.7) | 1 (2.7) | 0 (0.0) | 2 (5.4) | |||
| 15-29 | 75 | 30.9 | 3 (4.0) | 13 (17.3) | 1 (1.3) | 17 (22.7) | |||
| 30–44 | 83 | 34.2 | 6 (7.2) | 31 (37.3) | 4 (4.8) | 41 (49.4) | |||
| 45-59 | 26 | 10.7 | 3 (11.5) | 7 (26.9) | 1 (3.8) | 11 (42.3) | |||
| 60–74 | 16 | 6.6 | 0 (0.0) | 7 (43.8) | 2 (12.5) | 9 (56.3) | |||
| 75–80 | 06 | 2.5 | 1 (16.7) | 2 (33.3) | 0 (0.0) | 3 (50.0) | |||
| Total | 243 | 100 | 14 (5.8) | 61 (25.1) | 8 (3.3) | 83 (34.2) | |||
| X2 | 31.485 | ||||||||
| P-value | 0.000 | ||||||||
| Location | |||||||||
| KSUTH | 36 | 14.8 | 0 (0.0) | 13 (36.1) | 0 (0.0) | 13 (36.1) | |||
| MGH | 75 | 30.9 | 3 (4.0) | 19 (25.3) | 2 (2.7) | 24 (32.0) | |||
| PH | 39 | 16.0 | 2 (5.1) | 5 (12.8) | 4 (10.3) | 11 (28.2) | |||
| GCH | 3 | 21.8 | 6 (11.3) | 11 (20.8) | 0 (0.0) | 17 (32.1) | |||
| CGCH | 40 | 16.5 | 3 (7.5) | 13 (32.5) | 2 (5.0) | 18 (45.0) | |||
| Total | 243 | 100 | 14 (5.8) | 61 (25.1) | 8 (3.3) | 83 (34.2) | |||
| X2 | 3.02 | ||||||||
| P-value | 0.55 | ||||||||
Key: KSUTH = Kogi State University Hospital; MGH = Maria Gorethi Hospital; PH = Peace Hospital; GCH = Grimard Catholic Hospital, CGCH = Christ the Good shepherd Hospital; Abs = Antibodies; X2 = Chi square value.